



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 233/90, A61K 31/41 C07D 249/04	A1	(11) International Publication Number: WO 93/25536 (43) International Publication Date: 23 December 1993 (23.12.93)
(21) International Application Number: PCT/US93/05438 (22) International Filing Date: 8 June 1993 (08.06.93) (30) Priority data: 07/894,891 8 June 1992 (08.06.92) US 07/944,009 11 September 1992 (11.09.92) US 07/985,402 4 December 1992 (04.12.92) US (71) Applicant: THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Box OTT, Bethesda, MD 20892 (US). (72) Inventors: KOHN, Elise, C. ; 17703 Chipping Court, Olney, MD 20832 (US). LIOTTA, Lance, A. ; 9027 Mistwood Drive, Potomac, MD 20854 (US). FELDER, Christian, C. ; 5610 Southwick Street, Bethesda, MD 20817 (US).		(74) Agent: HEINES, M., Henry; Townsend and Townsend Khourie and Crew, Steuart Street Tower, 20th Floor, One Market Plaza, San Francisco, CA 94105 (US). (81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: 1,2,3-TRIAZOLE AND IMIDAZOLE COMPOUNDS AND THEIR ANTITUMOR USE (57) Abstract <p>A discovery underlying this invention is the concordance between particular cellular signaling mechanisms and cancer cell growth and metastasis. It has now been discovered that certain compounds inhibit the signal transduction required for the maintenance and driving of the malignant process. These compounds are also effective for the <i>in vivo</i> treatment of solid tumors and related disease states. This invention provides a method for the use of these compounds to inhibit the invasion and metastasis of malignant solid tumors in mammals. This invention further provides a method for using related compounds to treat diseases involving aberrant signal transduction pathways. Some of the compounds used in the methods of the present invention are novel and constitute another aspect of this invention.</p>		